Peptide Prescription Cost: What You'll Actually Pay in 2026

Why Peptide Costs Vary So Widely

Peptide prices depend on three things: the compound itself, how it is formulated, and who is prescribing it. A short-chain peptide like BPC-157 is cheaper to synthesize than a longer, more complex molecule like tesamorelin. Compounding pharmacy overhead, sterility testing, and shipping all add to the bill. Then there is the provider layer: some telehealth platforms bundle the consultation into a monthly membership while others charge separately for each visit.

The U.S. Food and Drug Administration does not have an approved New Drug Application for BPC-157, TB-500, or GHK-Cu in any indication, which means all three must come from a 503A or 503B compounding pharmacy operating under a valid prescription [1]. Section 503B outsourcing facilities face stricter current Good Manufacturing Practice (cGMP) requirements than 503A pharmacies, which generally makes their product cost slightly more [2]. Whether you pay for a 503A or 503B source is largely a decision your prescriber makes, not you, but it does affect the number on your invoice.

One additional cost driver: FDA enforcement posture. In 2023 the FDA placed BPC-157 and TB-500 on the "Difficult to Compound" list and later moved them to Category 2 substances under draft guidance [3]. This regulatory uncertainty pushed some compounding pharmacies out of the market, reducing supply and nudging prices upward by an estimated 15 to 25 percent from 2022 levels, based on pharmacy wholesale pricing data reviewed by the HealthRX medical team.

Learn more about FDA compounding regulations at FDA.gov

BPC-157 Cost: Monthly Breakdown

BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid peptide derived from a gastric protein sequence. A standard injectable protocol runs 200 to 500 mcg per day, five days per week, over 4 to 12 weeks [4]. At a 503A compounding pharmacy, a 10 mg vial sufficient for roughly 30 days at 300 mcg/day typically costs $120 to $200 before the provider markup.

After clinic or telehealth fees, most patients pay $150 to $300 per month for BPC-157 alone. Oral capsule formulations are cheaper ($60 to $120 per month) but carry lower bioavailability; injectable routes remain the standard when tissue repair is the goal [5].

A 2018 review in Current Pharmaceutical Design summarized the available animal data: BPC-157 accelerated tendon-to-bone healing in rat models and showed gastroprotective effects in multiple rodent studies, though no randomized controlled trial in humans had been completed at the time of that review [5]. The absence of human RCT data is the main reason insurers deny coverage.

View BPC-157 preclinical research on PubMed

Typical monthly all-in cost for BPC-157:

• Compounded injectable vial (10 mg): $120 to $200
• Syringes and bacteriostatic water (first month): $20 to $40
• Provider consultation (amortized monthly): $20 to $60
• Total range: $160 to $300 per month

TB-500 Cost: Monthly Breakdown

TB-500 is a synthetic fragment of Thymosin Beta-4, specifically the actin-binding domain (amino acids 17 to 23). Standard dosing protocols call for a loading phase of 4 to 8 mg per week for 4 to 6 weeks, followed by a maintenance phase of 2 to 2.5 mg per week [6]. Because the loading phase requires more compound, first-month costs run higher than subsequent months.

Expect to pay $250 to $400 in month one and $150 to $250 in maintenance months thereafter. Providers who bundle a quarterly supply can bring that per-month average to $200 to $350.

Research published in the Annals of the New York Academy of Sciences showed that Thymosin Beta-4 promoted cardiac stem cell migration and reduced infarct size in murine models, which is why it attracts interest in recovery protocols [7]. Human trial data remain limited, and this keeps TB-500 firmly in the off-label compounded category.

View Thymosin Beta-4 cardiovascular research on PubMed

TB-500 is slightly more expensive than BPC-157 per month because the typical therapeutic dose is higher by weight, meaning more active pharmaceutical ingredient per vial is required.

GHK-Cu Topical Cost: Monthly Breakdown

GHK-Cu (Glycyl-L-Histidyl-L-Lysine-Copper) is a naturally occurring copper complex found in human plasma, saliva, and urine. Plasma concentrations decline from roughly 200 ng/mL at age 20 to about 80 ng/mL by age 60, a drop that correlates with reduced skin repair capacity [8]. Compounded topical formulations attempt to restore local copper peptide activity.

Topical is the most affordable route. A 30 mL compounded GHK-Cu serum (typically 2 to 3 percent concentration) from a 503A pharmacy runs $70 to $150. Injectable GHK-Cu is prescribed less often but costs $150 to $300 per month when used subcutaneously for systemic effects.

A 2018 study in Biomolecules found that GHK-Cu upregulated 31 genes associated with collagen synthesis and downregulated 36 genes associated with inflammation in cell culture models [9]. The authors noted that the peptide "acts as a feedback signal that tissue has been damaged and needs repair," a finding that helps explain the clinical rationale behind topical protocols.

Read the GHK-Cu gene regulation study on PubMed

Monthly cost summary for GHK-Cu:

• Topical serum (30 mL, 2-3%): $70 to $150
• Injectable subcutaneous (2 to 4 mg per week): $150 to $300
• Provider fee (amortized): $20 to $50
• Total topical range: $90 to $200 per month

CJC-1295 and Ipamorelin Cost: Monthly Breakdown

CJC-1295 and Ipamorelin are almost always prescribed together. CJC-1295 is a growth hormone-releasing hormone (GHRH) analog; Ipamorelin is a growth hormone secretagogue that acts on the ghrelin receptor. The combination creates a synergistic pulse of endogenous GH release without significantly raising cortisol or prolactin, which is why this stack is popular in anti-aging and body-composition protocols [10].

A standard protocol uses 300 to 500 mcg of CJC-1295 paired with 200 to 300 mcg of Ipamorelin, injected subcutaneously at bedtime, 5 days per week. A combo vial from a 503A pharmacy typically costs $180 to $350 per month for the medication alone. With provider fees included, the total runs $250 to $450 per month.

Research published in the Journal of Clinical Endocrinology and Metabolism showed that modified GRF(1-29), the peptide structure behind CJC-1295, produced dose-dependent increases in serum GH and IGF-1 over a 28-day period, with peak IGF-1 increases of 30 to 100 percent from baseline at the 2 mg dose [11].

View GRF(1-29) pharmacokinetics on PubMed

Patients using this stack should budget for an IGF-1 blood test every 3 months ($50 to $120 depending on lab), since elevated IGF-1 carries its own risk profile and most responsible providers require monitoring.

Sermorelin and Tesamorelin Cost Comparison

Sermorelin is a 29-amino-acid GHRH analog and the most widely prescribed growth hormone secretagogue in the U.S. Its lower cost relative to CJC-1295/Ipamorelin comes from its simpler synthesis and longer market history. Monthly cost runs $150 to $300.

Tesamorelin (trade name Egrifta SV) is FDA-approved for HIV-associated lipodystrophy at 2 mg/day. Compounded tesamorelin for off-label use in body composition typically costs $300 to $550 per month, more than sermorelin because the molecule is larger and synthesis is more expensive. A 26-week randomized trial published in the New England Journal of Medicine (N=412) showed that tesamorelin 2 mg/day reduced visceral adipose tissue by 15.2 percent versus 1.5 percent for placebo (P<0.001) [12].

Read the tesamorelin RCT on NEJM

That RCT data is exactly why tesamorelin commands a premium: it has actual human evidence behind it, which makes prescribers more confident and pharmacies more willing to stock it.

Does Insurance Cover Peptides in 2026?

No major U.S. commercial insurer, Medicare, or Medicaid plan covers peptide therapy for performance, aesthetics, or anti-aging indications in 2026. This applies to BPC-157, TB-500, GHK-Cu, sermorelin, CJC-1295/Ipamorelin, and all other compounded peptides used off-label.

The one partial exception: tesamorelin (Egrifta SV) is covered under Medicare Part D and most commercial plans for HIV-associated lipodystrophy when billed under the branded drug, not as a compounded formulation [13]. For off-label body composition use, even tesamorelin goes uncovered.

Why the blanket exclusion? The Centers for Medicare and Medicaid Services (CMS) and commercial insurers require at least one FDA-approved indication before considering coverage. Compounded drugs, by definition, lack an approved NDA, so they fall outside standard formulary review processes entirely [14].

Review CMS compounded drug coverage policy

Health Savings Accounts (HSAs) and Flexible Spending Accounts (FSAs) are a gray area. If a licensed physician writes a prescription for a peptide to treat a diagnosed medical condition (for example, a tissue repair indication or a documented GH deficiency), some HSA administrators will accept the expense as a qualified medical cost. Patients should confirm with their HSA administrator in writing before submitting a claim.

The American Association of Clinical Endocrinology (AACE) guidelines on growth hormone deficiency state that GH stimulation testing with confirmed deficiency is required before initiating any GH-axis therapy, and that treatment should be monitored with serum IGF-1 every 3 to 6 months [15]. Meeting these criteria may improve the case for HSA reimbursement, though it does not guarantee it.

Read AACE GH guidelines at AACE.com

What Drives the Total Cost of a Peptide Protocol

The sticker price on a vial is only part of the equation. Here is where the money actually goes:

Consultation and ongoing monitoring. Initial consultations at telehealth platforms run $75 to $250. Some providers charge a monthly membership of $50 to $150 that covers messaging, prescription management, and one check-in call per quarter.

Lab work. A baseline panel for someone starting a GH secretagogue typically includes IGF-1, fasting glucose, HbA1c, and a comprehensive metabolic panel. Depending on the lab and whether the patient has insurance for diagnostics, this costs $80 to $250 per draw. Quarterly monitoring adds $40 to $150 per panel if IGF-1 alone is checked.

Supplies. Subcutaneous injection supplies (insulin syringes, alcohol wipes, sharps container) run $15 to $30 per month for most protocols.

Shipping. Compounding pharmacies typically charge $15 to $30 for cold-chain shipping, since most injectable peptides require refrigeration.

A realistic all-in monthly budget for a single injectable peptide protocol:

| Component | Low estimate | High estimate | |---|---|---| | Compound (vial) | $120 | $400 | | Supplies | $15 | $30 | | Shipping | $15 | $30 | | Provider fee (amortized) | $20 | $80 | | Lab monitoring (amortized) | $20 | $70 | | Total | $190 | $610 |

How to Evaluate Whether a Peptide Price Is Fair

A few markers separate legitimate compounding pharmacies from gray-market suppliers. PCAB accreditation (Pharmacy Compounding Accreditation Board) signals that a pharmacy meets independent quality standards. A valid prescription requirement is non-negotiable. Sterility and potency certificates of analysis (COA) should be available on request.

Prices below $80 per month for injectable peptides should raise a flag. Synthesis below that price point is nearly impossible to achieve while covering sterility testing, proper cold-chain storage, and cGMP-adjacent quality controls. A 2022 analysis published in JAMA found that patients purchasing compounded medications from non-accredited online pharmacies had a 34 percent rate of subpotent or contaminated products [16].

Read compounded drug quality data on JAMA

Conversely, prices above $600 per month for a single standard peptide (not a multi-compound protocol) are likely inflated. At that level, you are paying for a clinic's overhead rather than a better product.

Stacking Multiple Peptides: Cost Considerations

Stacking two or more peptides is common in performance-oriented protocols. A typical example: BPC-157 (for tissue repair) combined with CJC-1295/Ipamorelin (for GH pulse and recovery). Each compound requires its own prescription, its own vial, and its own dosing schedule.

Combined monthly costs for a two-peptide stack run $350 to $700. A three-compound protocol (adding GHK-Cu topical, for example) can reach $450 to $850 per month. Providers who offer bundled pricing for multi-compound protocols may reduce the per-compound cost by 10 to 20 percent.

Patients should ask their provider explicitly whether there are known interaction risks before starting a stack. BPC-157's proposed mechanism involves the NO-system and growth factor pathways, which theoretically could interact with GH-axis peptides, though no human pharmacokinetic interaction studies have been published as of early 2025 [5].

Telehealth vs. In-Clinic Pricing

Telehealth platforms have reduced the consultation cost barrier substantially. A telehealth visit for peptide therapy runs $75 to $150, compared to $200 to $400 for an in-person visit at a specialized anti-aging or functional medicine clinic. The medication cost is roughly the same because both typically use the same network of compounding pharmacies.

The trade-off is clinical depth. An in-person provider can perform a physical exam, review imaging, and assess injection technique. For complex indications (suspected GH deficiency, significant tissue injury, or dermatological conditions where GHK-Cu is being used), the $100 to $200 price difference for in-person care may be worth it.

The Endocrine Society's 2019 clinical practice guideline on GH deficiency in adults states: "We recommend against diagnosing GHD in adults without biochemical confirmation using an appropriate GH stimulation test" [17]. A telehealth provider who prescribes GH-axis peptides without any IGF-1 or stimulation testing is not meeting that standard, regardless of cost.

Read the Endocrine Society GHD guideline at Endocrine.org

Reducing Out-of-Pocket Peptide Costs

Several practical steps can lower what you pay:

First, consolidate lab work. Order all baseline and follow-up panels at once rather than in separate draws. A panel covering IGF-1, HbA1c, CBC, and CMP in one draw costs $100 to $180; ordering them separately over multiple visits may cost $250 to $400 for the same tests.

Second, ask about quarterly vial sizing. A 30 mg vial of BPC-157 covering 90 days at 300 mcg/day often costs less per milligram than three separate 10 mg vials. Not every pharmacy offers this, but it is worth asking.

Third, compare 503A pharmacies. Your prescriber must write to a specific pharmacy, but you can ask whether your provider works with multiple compounding pharmacies and which offers the best pricing for your compound. Some telehealth platforms have negotiated pharmacy rates that pass savings to the patient.

Fourth, time your protocol around your calendar. Most peptide protocols last 8 to 12 weeks followed by a 4-week break. A structured cycle means you pay for 2 to 3 months on and 1 month off, reducing the annual cost by roughly 20 to 25 percent compared to continuous use.

Peptide Prescription Cost: Red Flags and Green Lights

Green lights when evaluating a peptide provider:

• Requires a prescription and routes it to a licensed U.S. compounding pharmacy
• Requests baseline labs before prescribing GH-axis peptides
• Provides a COA from the compounding pharmacy on request
• Prices fall in the expected ranges outlined above

Red flags:

• Ships peptides internationally with no prescription required
• Prices below $80 per month for injectable compounds
• No lab monitoring requirement for GH-axis peptides
• Cannot name the compounding pharmacy used

The FDA's BeSafeRx campaign identifies unlicensed online pharmacies as a primary source of substandard compounded products, and the agency maintains a list of safe online pharmacy criteria at its website [18].

Review FDA BeSafeRx guidelines

A standard 12-week BPC-157 protocol at $200 per month totals $600. That is a meaningful out-of-pocket spend. Spending it with a licensed provider who monitors your response costs the same as spending it on an unverified product that may contain 60 percent of the labeled dose.